{
  "authorized_claims": [
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "EPA and DHA contribute to the normal function of the heart.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2): claim may be used only for food which provides a daily intake of at least 250 mg of EPA and DHA, and the consumer must be informed that the beneficial effect is obtained with a daily intake of 250 mg of EPA and DHA"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "DHA contributes to the maintenance of normal brain function.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2): claim may be used only for food which contains at least 40 mg of DHA per 100 g and per 100 kcal; consumer informed that the beneficial effect is obtained with a daily intake of 250 mg of DHA"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "DHA contributes to the maintenance of normal vision.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2): claim may be used only for food which contains at least 40 mg of DHA per 100 g and per 100 kcal; consumer informed that the beneficial effect is obtained with a daily intake of 250 mg of DHA"
    },
    {
      "market": "ANVISA",
      "framework_reference": "IN 28/2018 Anexo V alegação funcional",
      "claim_verbatim": "Os ácidos graxos ômega 3 EPA e DHA auxiliam na redução dos triglicerídeos.",
      "authorization_date": "2018",
      "conditions": "IN 28/2018 Anexo V: alegação restrita a suplementos que forneçam ao menos 1.500 mg de EPA + DHA por dia"
    }
  ],
  "slug": "algal-oil",
  "name": "Algal Oil (Microalgae-Sourced DHA · EPA · DHA blends)",
  "alternate_names": [
    "Microalgal DHA",
    "Vegan DHA",
    "Schizochytrium DHA",
    "Crypthecodinium DHA"
  ],
  "mechanism": [
    "Direct dietary delivery of DHA (and increasingly EPA) without the marine-fish food chain",
    "Cell membrane phospholipid integration",
    "Same downstream pathways as fish-oil EPA/DHA (SPM biosynthesis, GPR120/FFAR4, PPAR-α)"
  ],
  "target": [
    "Cell membranes",
    "Cardiovascular outcomes via EFSA-authorized claims",
    "Cognitive / visual DHA pool support"
  ],
  "use_case": [
    "vegan / vegetarian EPA + DHA adequacy",
    "fish-allergic adults",
    "pregnancy DHA supplementation when avoiding fish"
  ],
  "body_system": [
    "CARDIO",
    "NEURO",
    "VISION"
  ],
  "evidence_tier": "A",
  "evidence_anchor_pmid_count": 1,
  "dosage_range": "250 mg combined EPA + DHA daily meets the EFSA cardiovascular threshold; 200-300 mg DHA daily for cognitive and visual maintenance per EFSA. Arterburn 2007 PMID 17713804 Lipids 28-day randomized, placebo-controlled, parallel-group bioavailability study (n = 12 per group · four groups including algal-oil capsules and a DHA-fortified food) demonstrated algal-oil DHA bioequivalence at 200 / 600 / 1,000 mg doses with linear, dose-dependent plasma phospholipid DHA response",
  "safety_notes": "Excellent safety profile; no heavy-metal contamination concerns (microalgal cultivation is closed-system); confirm allergen disclosure for individuals with specific algal sensitivities; check for added vitamin E if antioxidant adequacy is monitored separately",
  "regulatory": {
    "fda": "GRAS · DSHEA dietary supplement · ω-3 qualified health claims under the omega-3 framework (CHD risk reduction · 2003Q-0401; blood pressure · 2014Q-0337) when EPA+DHA dose meets the food-labelling threshold",
    "efsa": "Authorized claims Reg 432/2012 (cardiovascular, brain, vision) when EPA+DHA / DHA per-serving threshold reached",
    "anvisa": "RDC 243/2018 dietary supplement · IN 28/2018 Anexo V alegação funcional verbatim: \"Os ácidos graxos ômega 3 EPA e DHA auxiliam na redução dos triglicerídeos.\" (≥ 1.500 mg EPA+DHA/dia)"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/algal-oil/",
  "related_goal_slugs": [
    "heart-health",
    "cognitive-support",
    "eye-protection",
    "reproductive-health"
  ],
  "related_lifestyle_slugs": [
    "plant-based",
    "pregnancy",
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-04",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-04",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}